Debecarasib is an orally bioavailable inhibitor that noncovalently binds the oncogenic KRAS G12D mutant protein, with higher affinity for its GDP-bound conformation. It is being studied in pancreatic ductal adenocarcinoma, non-small cell lung cancer, and colorectal cancer.
Summary written with AI from the sources listed at the end of this page.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.